(Boursier.com) — Genomic Visiona biotechnology company that develops products and services dedicated to the analysis and control of genome modifications, announces today the issuance of the second tranche of bonds convertible into shares accompanied by share subscription warrants ( OCABSA) for a net amount of 1.920 million euros.
It is reminded that in the context of a press release dated May 20, 2022, the company had announced the signing of an issue contract on April 11, 2022 as amended on May 18, 2022 with Winance with a view to establishment of a financing line by issuing bonds convertible into ordinary shares, to each of which will be attached a share subscription warrant, for a maximum total net amount of 28.8 ME (30 ME nominal value).
The extraordinary general meeting of shareholders of the company which met on May 23, 2022 approved the implementation of this financing.
©2023 Boursier.com